Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0021831 (
enteropathy
)
4,403
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mucosal graft-versus-host reaction (GvHR) of the small intestine exemplifies an immunologically mediated
enteropathy
that is associated with expansion of mucosal mast cells (MMC). Quantitative measures of intestinal morphology, epithelial cell kinetics and mucosal immune activity were used to assess the effect of the immunosuppressive agent, cyclosporin A (CyA), in ameliorating this
enteropathy
and on increased activity of MMC in the jejunum. GvHR was induced in two groups of PVGU x PVGC rats by irradiation (4.50 Gy) and intravenous injection of PVGC spleen cells (150 x 10(6)). One group remained untreated, while a second group of eight rats was treated with a 50 mg/kg dose of CyA subcutaneously given daily for the first 3 days and then every second day, and which had commenced the day before induction of GvHR. On day 14, all animals were killed. Treatment with CyA prevented intestinal crypt hyperplasia but did not affect villus length, and normalized the crypt cell production rate (CCPR) from 38 to 15 cells/crypt/h (P less than 0.0001). CyA reduced the number of MMC and jejunal content of the MMC associated protease, rat mucosal
mast cell protease II
(RMCPII). Mean serum RMCPII concentration was reduced from 302 (s.d. = 112) in GvHR animals to 10 (s.d. = 6) ng/mL in GvHR/CyA-treated rats (P less than 0.0001). We conclude that CyA ameliorates the
enteropathy
of GvHR and depresses the activation of MMC, as evident by the strongly depressed serum RMCPII concentration.
...
PMID:Effect of cyclosporin A treatment on the enteropathy of graft-versus-host reaction in the rat: a quantitative study of intestinal morphology, epithelial cell kinetics and mucosal immune activity. 267 54
T cell mediated immune responses in the gut can produce
enteropathy
and malabsorption. We have investigated the relevance of mucosal mast cells (MMC) to the mechanisms of this
enteropathy
by using graft-versus-host reaction (GvHR) in the rat as a model of mucosal delayed type hypersensitivity. Measurements of mucosal architecture, intraepithelial lymphocytes (IEL) and MMC counts were performed in control and experimental rats, and release of
rat mast cell protease II
(RMCPII) into the bloodstream was used as an index of MMC activation. In unirradiated rats, jejunal MMC count was increased on day 14 of the GvHR (mean 272/mm2 v 182 in controls, p less than 0.01), as was serum RMCPII (p less than 0.01). Irradiated rats (4.5 Gy, reconstituted with isogeneic spleen cells) had low counts of IEL and crypt hyperplasia seven to 14 days after irradiation. Irradiated rats with GvHR (induced by ip injection of parental strain spleen cells) and studied on days 7, 10 and 14, had significant
enteropathy
with longer crypts and higher CCPR than matched irradiated animals (p less than 0.05 on day 14 when compared with irradiation alone). Intraepithelial lymphocytes counts, however, reflected only the effect of radiation. Irradiation, with or without GvHR, led to the virtual disappearance of jejunal MMC, undetectable jejunal RMCPII and very low levels of RMCPII in serum (all p less than 0.01 when compared with unirradiated controls). These experiments show that there is a modest expansion in jejunal MMC in unirradiated rats with semiallogeneic GvHR, whereas irradiation, alone or associated with GvHR, profoundly depletes MMC for at least two weeks. The
enteropathy
of GvHR can evolve in the virtual absence of MMC.
...
PMID:Separate effects of irradiation and of graft-versus-host reaction on rat mucosal mast cells. 270 34
In this study subtypes, distribution and number of mast cells were investigated within mucosa and submucosa of the gastrointestinal tract of 24 cats with inflammatory bowel disease (IBD) in comparison to 11 control cats. Paraffin sections of formalin-fixed transmural gastrointestinal biopsies from stomach, duodenum, jejunum, ileum and colon were examined. Mast cells were phenotyped and quantified based on their chymase and
tryptase
content, by applying a combined enzyme-histochemical and immunohistochemical double-labeling technique and on their heparin content by a metachromatic staining method (kresylecht-violet, MC(KEV)). Mast cells containing both chymase and
tryptase
were not found in any of the samples examined. Furthermore, in the stomach neither chymase (MC(C)) nor
tryptase
(MC(T)) bearing mast cells were detected. In cats with lymphocytic-plasmacytic enteritis or enterocolitis elevated numbers of MC(T) or MC(C) were identified in comparison to controls mainly located in the inflamed segments. The highest quantity of MC(C) was found in cats with eosinophilic gastroenterocolitis or enterocolitis in comparison to other IBD forms, but only minor numbers of MC(T) were detected in these cases. In cats with fibrosing
enteropathy
(FE) a decrease of MC(C) and mast cells containing heparin was detected in affected segments, while increased numbers of MC(T) were detected in all locations. The elevation in the number of MC(T) was higher in unaffected areas than in fibrotic regions. Regarding all IBD cases higher counts of MC(C) were found especially in the inflamed locations, whereas in unaffected segments increased numbers of MC(T) were detected. The clear predominance of MC(C) and MC(T) within the mucosa and of MC(KEV) within the submucosa of all cats examined possibly represents differences of the cytokine milieu within the intestinal layers. In FE, mast cells are possibly pivotal for the containment of the inflammatory process because of their antiinflammatory properties. The results of this study indicate that mast cells and their mediators are involved in the pathogenesis of different IBD forms in cats.
...
PMID:Phenotypical characterization, distribution and quantification of different mast cell subtypes in transmural biopsies from the gastrointestinal tract of cats with inflammatory bowel disease. 2064 65